# Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL

> **NCT07554820** · PHASE4 · RECRUITING · sponsor: **Shaikh Zayed Hospital, Lahore** · enrollment: 120 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Major Adverse Cardiac Events

## Interventions

- **DRUG:** Tofacitinib 5 MG

## Key facts

- **NCT ID:** NCT07554820
- **Lead sponsor:** Shaikh Zayed Hospital, Lahore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-06
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07554820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07554820, "Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07554820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*